TORONTO, Aug. 25 /CNW/ - NeuroMedix Inc. (“NeuroMedix”) (TSXV: NMX) today announced that it has produced its first kilogram-scale batch of clinical grade cGMP (current Good Manufacturing Practice) Minozac for late stage pre-clinical toxicology studies and for human safety Phase I studies.
